Home

Alpha Cognition Inc. - Common Stock (ACOG)

5.9000
-0.0400 (-0.67%)
NASDAQ · Last Trade: Nov 17th, 8:07 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Alpha Cognition Inc. (NASDAQ:ACOG) Reports Q3 2025 Revenue Beat and Strong Commercial Progress for ZUNVEYLchartmill.com
Alpha Cognition's Q3 2025 results beat revenue estimates by 37% on strong sales of its Alzheimer's drug, ZUNVEYL, showing significant commercial momentum.
Via Chartmill · November 13, 2025
Earnings Scheduled For November 13, 2025benzinga.com
Via Benzinga · November 13, 2025
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga.com
Via Benzinga · September 30, 2025
Earnings Scheduled For August 14, 2025benzinga.com
Via Benzinga · August 14, 2025
Why ServiceNow Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · April 24, 2025
Earnings Scheduled For May 15, 2025benzinga.com
Via Benzinga · May 15, 2025
Earnings Scheduled For March 31, 2025benzinga.com
Via Benzinga · March 31, 2025
Alpha Cognition Is 'Under-Followed' As Alzheimer Drug Targets $2 Billion Long Term Care Market: Analystbenzinga.com
HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm.
Via Benzinga · March 18, 2025
This West Pharmaceutical Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesdaybenzinga.com
Via Benzinga · March 18, 2025
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In Chinabenzinga.com
Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits for blast-related brain injuries.
Via Benzinga · January 8, 2025
Invizyne Technologies Jumps After IPOtalkmarkets.com
Invizyne Technologies opened on Nov. 13 at $11.10. Shares gained as much as 13% following the company's $15 million initial public offering. Additionally, Alpha Cognition opened on Nov. 12 at $7.00.
Via Talk Markets · November 17, 2024